Dr Agarwal’s Health Care shares rose 5.5 per cent on Wednesday after the company reported strong first-quarter FY27 results.The stock traded at ₹515.80 on the NSE after touching an intraday high of ₹520.90, compared with the previous close of ₹493.50.Profit after tax surged 44.6 per cent to ₹55 crore, outpacing revenue growth even as the company absorbed higher greenfield investments.The company reported revenue from operations rising 26 per cent y-o-y to ₹614 crore. EBITDA increased 25.2 per cent to ₹177 crore, while EBITDA margin remained resilient at 28.5 per cent.The quarter also marked the company’s largest-ever quarterly expansion of new eye care centres. Separately, the board approved the incorporation of a wholly owned subsidiary in Nigeria.Morgan Stanley maintained an overweight rating and raised its target price to ₹576 from ₹555. The brokerage said the company delivered an impressive quarter, with revenue growing 26 per cent y-o-y and same-store sales growth of 16 per cent.It said management expects same-store sales growth to normalise over time, while premiumisation-led growth, a large untapped market opportunity, robust expansion visibility and improving return on capital employed support the outlook. Morgan Stanley added that the valuation remains attractive.Jefferies reiterated its accumulate rating and increased its target price to ₹600 from ₹510. The brokerage said strong execution continued during the June quarter, with expansion across all regions. It expects mid-teens volume growth along with premiumisation and said same-store sales growth continues to remain robust.More Like ThisPublished on August 5, 2026